IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.28
-0.67 (-6.12%)
At close: 4:00PM EDT

10.28 0.00 (0.00%)
After hours: 5:17PM EDT

Stock chart is not supported by your current browser
Previous Close10.95
Open11.02
Bid9.90 x 1400
Ask10.41 x 1800
Day's Range10.25 - 11.20
52 Week Range7.60 - 17.76
Volume876,930
Avg. Volume1,404,280
Market Cap1.6B
Beta (3Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 100 Summer lands WeWork ahead of tower's possible sale
    American City Business Journals3 days ago

    100 Summer lands WeWork ahead of tower's possible sale

    Co-working giant WeWork is leasing yet another office in Boston, this time a 117,000-square-foot, three-floor spot at 100 Summer St. WeWork will house 2,300 desks at the tower, which Blackstone owns through its EQ Office arm.

  • Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD)
    Insider Monkey4 days ago

    Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD)

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the first quarter and hedging or reducing many of their […]

  • Company News For Jun 20, 2019
    Zacks4 days ago

    Company News For Jun 20, 2019

    Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD

  • Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients
    Zacks5 days ago

    Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients

    Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pain and discomfort in IBS-C patients.

  • Benzinga5 days ago

    Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective

    Ironwood and Allergan plc (NYSE: AGN) announced positive topline results from a Phase 3b study evaluating Linzess 290 mcg for multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation, or IBS-C. The companies said the late-stage study met the primary multicomponent endpoint of the drug, when administered orally once-daily, demonstrating an improvement in overall abdominal symptoms of bloating, pain and discomfort in adult patients with IBS-C compared to placebo. Linzess, an FDA-approved drug for IBS-C or chronic idiopathic constipation, or IDC, is marketed in the U.S. by Ironwood and Allergan.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding IRWD are favorable, with net inflows of $2.49 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Cambridge’s Ironwood Pharma moving HQ to downtown Boston
    American City Business Journals11 days ago

    Cambridge’s Ironwood Pharma moving HQ to downtown Boston

    The move comes after longtime Ironwood CEO Peter Hecht left the company to lead spinoff Cyclerion Therapeutics.

  • Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
    Zacks19 days ago

    Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

    Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

  • Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report?
    Zacks23 days ago

    Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report?

    Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Barrons.comlast month

    Sarissa Capital Is Drawn to Ironwood Pharmaceuticals

    On the same day, Marathon issued a letter to e.l.f.’s board that questioned moves by the company to “vary equity grant dates, earnings release dates, forward guidance, and fiscal year end” over the past three years. Marathon said the company acted in a “deliberate manner that consistently benefited [e.l.f.’s] executives” at the expense of shareholders. Marathon also stated that the best remedy for this situation would be to bring aboard additional, fully independent directors, including someone designated to the compensation committee.

  • Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today
    Motley Foollast month

    Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today

    An SEC filing shows an activist investor is building a sizable position in the company.

  • 6 Positions the Vanguard Health Care Fund Continues to Increase
    GuruFocus.comlast month

    6 Positions the Vanguard Health Care Fund Continues to Increase

    CVS Health tops the list

  • Thomson Reuters StreetEventslast month

    Edited Transcript of IRWD earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Ironwood Pharmaceuticals Inc Earnings Call

  • Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%?
    Simply Wall St.2 months ago

    Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors can approximate the average market return by buying an index fund. While individual st...

  • Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall
    Zacks2 months ago

    Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall

    Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.

  • Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript

    IRWD earnings call for the period ending March 31, 2019.

  • Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

    Ironwood (IRWD) delivered earnings and revenue surprises of -62.50% and -17.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Ironwood: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 38 cents per share. Losses, adjusted for non-recurring costs and restructuring costs, came to 26 cents per share. The results missed Wall ...

  • Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks2 months ago

    Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Will Ironwood Suffer From Dependence on Linzess' Progress?
    Zacks3 months ago

    Will Ironwood Suffer From Dependence on Linzess' Progress?

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

  • As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start'
    American City Business Journals3 months ago

    As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start'

    "To be clear, this is not a division between commercial and R-and-D priorities," new Cyclerion CEO Pete Hecht said of the split between the company he founded, Ironwood Pharmaceuticals, and his new firm.